Brincidofovir clearance of acyclovir‐resistant herpes simplex virus‐1 and adenovirus infection after stem cell transplantation | Zendy

Voigt S. | Zendy; Hofmann J. | Zendy; Edelmann A. | Zendy; Sauerbrei A. | Zendy; Kühl J.S. | Zendy

Premium

Brincidofovir clearance of acyclovir‐resistant herpes simplex virus‐1 and adenovirus infection after stem cell transplantation

Author(s) -

Voigt S.,

Hofmann J.,

Edelmann A.,

Sauerbrei A.,

Kühl J.S.

Publication year - 2016

Publication title -

transplant infectious disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.69

H-Index - 67

eISSN - 1399-3062

pISSN - 1398-2273

DOI - 10.1111/tid.12582

Subject(s) - medicine , cidofovir , herpes simplex virus , mucositis , virology , hematopoietic stem cell transplantation , viral load , stem cell , meningoencephalitis , adenovirus infection , transplantation , simplexvirus , immunology , virus , aciclovir , herpesviridae , viral disease , chemotherapy , biology , genetics

Infections with adenovirus (AdV) and herpesviruses can result in considerable morbidity and mortality in pediatric hematopoietic stem cell transplant ( SCT ) recipients. Herpes simplex virus ( HSV ) reactivations are usually prevented by acyclovir ( ACV ) prophylaxis, whereas cidofovir ( CDV ) has been used off indication to manage AdV infections. We report a child with myelodysplastic syndrome undergoing multiple SCT , who experienced HSV ‐1 disease including severe mucositis and herpetic whitlow, as well as high viral load AdV DNA emia. Both ACV and CDV were ineffective; however, viral loads were decreased with brincidofovir, resulting in viral clearance. A subsequent Epstein–Barr virus disease with relevant meningoencephalitis responded to rituximab.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research